From Regulatory Affairs To R&D, Sanofi’s Mura Has Broad Strategic View
Sanofi’s Raquel Mura Hopes Her Example Will Show Other Women The Opportunity In Life Sciences
From a legal family in her native Brazil, Raquel Mura built on her passion for science to work in consumer health care, nutritionals and pharmaceuticals, rising to an R&D leadership position at Sanofi.
You may also be interested in...
The FDA placed a hold on the Phase II study of SRP-5051, which uses the company’s next-generation peptide conjugation technology, but Sarepta thinks it can address safety questions in short order.
F-star's novel bispecific technology attracts Sino Biopharma-affiliated acquisition, Shionogi agreement with GARDP brings antibiotic cefiderocol to 135 countries, deal with WinHealth covering Greater China expands Quoin’s licensing of Netherton syndrome candidate to 60 nations, Kyorin and CellGenTech team up in Fabry disease.
A new EY report contends that declining biotech valuations and the need for large pharma to add pipeline assets may create conditions for a buyer’s market – although year-to-date M&A activity has been lackluster.